Evidence map›Paper›PMID 41334477›Full record

ArticleJugan geon-gang gwa jilbyeong2023

[2021-2022 Influenza and Respiratory Viruses Laboratory Surveillance Report in the Republic of Korea].

Nam-Joo Lee, SangHee Woo, Jaehee Lee, Jee Eun Rhee, Eun-Jin Kim

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nam-Joo Lee질병관리청 감염병진단분석국 신종병원체분석과.
SangHee Woo질병관리청 감염병진단분석국 신종병원체분석과.
Jaehee Lee질병관리청 감염병진단분석국 신종병원체분석과.
Jee Eun Rhee질병관리청 감염병진단분석국 신종병원체분석과.
Eun-Jin Kim질병관리청 감염병진단분석국 신종병원체분석과.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The surveillance of influenza and respiratory viruses was conducted from 36 weeks in 2021 to 35 weeks in 2022. Respiratory specimens were collected from patients with influenza in 77 private clinics. During the 2021-2022 flu season, 5,959 specimens were collected; the diagnosis was made using multiplex RT-PCR. Findings indicated that 38 cases were positive for influenza. All these cases were confirmed to be infections with influenza A(H3N2) and were genetically and antigenically similar to the strains observed in the 2021-2022 and 2022-2023 seasons. Additionally, all isolated influenza viruses were susceptible to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir). During this period, rhinovirus had the highest incidence (21.8%), followed by the respiratory syncytial virus (11.3%), parainfluenza virus (10.5%), bocavirus (5.1%), adenovirus (4.6%), human coronavirus (3.3%), and metapneumovirus (0.4%). In the 2020-2021 season, the influenza virus was not detected; however, in the 2021-2022 season, it was consistently at a low activity after 27 weeks. Further, among respiratory viruses, the detection rate of enveloped viruses increased, unlike during the 2020-2021 season, when non-enveloped viruses (rhinovirus, adenovirus, and bocavirus) were prevalent. It is presumed that changes in various quarantine policies, increase in social activities, and low herd immunity due to low morbidity of other respiratory infectious diseases during the coronavirus disease 2019 outbreak influenced the increased detection of influenza and respiratory viruses. Accordingly, we will continue to monitor changes in outbreaks closely and analyze virus characteristics through the Korea Respiratory Virus Integrated Surveillance System.

Indexed as

InfluenzaRespiratory virusesSurveillance

Identifiers

PMID41334477
PMCPMC12480087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.